BRIAN WEBER: Open Payments
NPI 1255313763 · COMMERCE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$901 in 49 payments from 18 companies in 2025. Trend: 2023 $983 · 2024 $1,081 · 2025 $901
Food & beverage: $901
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $220 |
| GlaxoSmithKline, LLC. | 10 | $154 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| PFIZER INC. | 3 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $70 |
| Novo Nordisk Inc | 3 | $53 |
| ABIOMED | 1 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| Viatris Specialty LLC | 1 | $20 |
Products named: VRAYLAR, TRELEGY ELLIPTA, AUSTEDO XR, ELIQUIS, CAPLYTA, LINZESS, REXULTI, YUPELRI.
Industry payments across TX — which companies pay providers there.
